양성자 펌프 억제제 시장 : 유형별, 적응증별, 제형별, 유통 채널별, 지역별

Global proton pump inhibitors market is estimated to be valued at USD 3.81 Bn in 2024 and is expected to reach USD 5.50 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.4% from 2024 to 2031.

Figure 1. Proton Pump Inhibitors Market Share (%), By Region, 2024

Proton pump inhibitors (PPIs) are a group of medicines that work by reducing the amount of acid produced in the stomach. PPIs are commonly used to treat acid reflux, ulcers, and inflammation of the esophagus. These work by blocking the action of the proton pump, an enzyme on the surface of gastric parietal cells. This enzyme is responsible for transportation of ions that aid in the production of hydrochloric acid in the stomach. By inhibiting this pump, PPIs decrease acid production and offer relief from conditions caused by excess stomach acid. Growing prevalence of acid related diseases, increasing aging population suffering from such diseases, rising healthcare expenditure can drive the global proton pump inhibitors market growth in the near future.

Market Dynamics:

Rising prevalence of acid-related diseases such as peptic ulcer disease and gastroesophageal reflux disease (GERD) around the world can drive the global proton pump inhibitors market growth. GERD has become highly common worldwide due to changing dietary patterns and lifestyle changes. According to some estimates, GERD affects over 20% of the population in North America. Proton pump inhibitors are first line treatment for GERD patients. Growing geriatric population can also drive the market growth as older people are more prone to acid-related disorders. However, side effects associated with long-term PPI usage such as kidney problems, bone fractures, pneumonia, and interference with absorption of nutrients can hamper the market growth. Growing awareness regarding digestive health and rising healthcare expenditure in emerging nations can offer opportunities for the market players.

Key Features of the Study:

• This report provides in-depth analysis of the global proton pump inhibitors market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global proton pump inhibitors market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include AstraZeneca, Pfizer, Johnson and Johnson, and Bayer
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global proton pump inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global proton pump inhibitors market

Detailed Segmentation-

• By Type
  • Omeprazole
  • Pantaprazole
  • Rabeprazole
  • Dexlansoprazole
  • lansoprazole
  • Others
• By Disease Indication
  • Ulcers
  • Gastroesophageal Reflux Disease
  • Others
• By Dosage Form
  • Tablet
  • Capsules
  • Injection
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • AstraZeneca
  • Pfizer
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • Procter & Gamble
  • Johnson & Johnson
  • GlaxoSmithKline plc
  • Bayer AG
  • Eisai Co., Ltd.
  • Merck & Co., Inc.
  • Reddy's Laboratories Ltd.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Sun Pharmaceutical Industries Ltd.
  • Allergan, Inc.
  • Cadila Pharmaceuticals
  • Daiichi Sankyo Company, Limited
  • Perrigo Company PLC

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Type
  • Market Snapshot, By Disease Indication
  • Market Snapshot, By Dosage Form
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Proton Pump Inhibitors Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Proton Pump Inhibitors Market, By Type, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Omeprazole
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Pantaprazole
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Rabeprazole
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Dexlansoprazole
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Lansoprazole
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Proton Pump Inhibitors Market, By Disease Indication, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Ulcers
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Gastroesophageal Reflux Disease
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Proton Pump Inhibitors Market, By Dosage Form, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Tablet
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Capsules
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Injection
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Proton Pump Inhibitors Market, By Dosage Form, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

9. Global Proton Pump Inhibitors Market, By Region, 2019 - 2031, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2031
  • Regional Trends
    • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

10. Competitive Landscape

• Company Profiles
  • AstraZeneca
    • Company Highlights
    • Disease Indication Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Pfizer
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • Procter & Gamble
  • Johnson & Johnson
  • GlaxoSmithKline plc
  • Bayer AG
  • Eisai Co., Ltd.
  • Merck & Co., Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Sun Pharmaceutical Industries Ltd.
  • Allergan, Inc.
  • Cadila Pharmaceuticals
  • Daiichi Sankyo Company, Limited
  • Perrigo Company PLC.

11. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. Reference and Research Methodology

• References
• Research Methodology
• About us and Sales Contact